• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Vivimedlab Share Price

    Vivimed Labs Share PriceVivimed Labs

    Small Cap 3.4k Result
    ₹4.9
    -0.1 (-2%)
    As on 30 September, 2023 | 05:31 BSE: 532660 NSE: VIVIMEDLABISIN: INE526G01021

    Vivimed Labs Performance

    Day Range

    • Low 4.85
    • High 5.25
    4.9

    52 Week Range

    • Low 4.85
    • High 13.95
    4.9
    • Open Price5.25
    • Previous Close5
    • Volume151690

    Start SIP in Vivimed Labs

    Start SIP

    Vivimed Labs Share Price

    • Over 1 Month -14.04%
    • Over 3 Month -24.62%
    • Over 6 Month -50.25%
    • Over 1 Year -52.66%

    Vivimed Labs Key Statistics

    P/E Ratio -0.1
    PEG Ratio 0
    Market Cap Cr 41
    Price to Book Ratio 1
    EPS -39.6
    Dividend 0
    Relative Strength Index 16.76
    Money Flow Index 11.32
    MACD Signal -1.03
    Average True Range 0.44

    Vivimed Labs Investment Rating

    • Master Rating:

    • Vivimed Labs has an operating revenue of Rs. 172.34 Cr. on a trailing 12-month basis. An annual revenue de-growth of -21% needs improvement, Pre-tax margin of -177% needs improvement, ROE of -833% is poor and needs improvement. The company has a high debt to equity of 158%, which can be a reason to worry. From an O'Neil Methodology perspective, the stock has an EPS Rank of 17 which is a POOR score indicating inconsistency in earnings, a RS Rating of 2 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 111 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of E is the worst. Institutional holding has remained stable in the last reported quarter. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Vivimed Labs Financials
    IndicatorJun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 334051394753
    Operating Expenses Qtr Cr 3320357495655
    Operating Profit Qtr Cr 0-164-6-10-9-2
    Depreciation Qtr Cr 4954445
    Interest Qtr Cr 11899910
    Tax Qtr Cr 0-20003
    Net Profit Qtr Cr -15-265-19-22-22-19
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 177220
    Operating Expenses Annual Cr 365228
    Operating Profit Annual in Cr -188-9
    Depreciation Cr 10717
    Interest Annual Cr 3540
    Tax Annual Cr -23
    Net Profit Annual Cr -328-68
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 25
    Cash from Investing Activity Annual Cr -11
    Cash from Financing Annual Activity Cr -13
    Net Cash Flow Annual Cr 1
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 133457
    Fixed Assets Annual Cr 364469
    Total Non Current Assets Annual Cr 525630
    Total Current Assets Annual Cr 268442
    Total Assets Annual Cr 7921,072
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 1655
    ROE Annual % -246-16
    ROCE Annual % -78-4
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % -106-4
    IndicatorJun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 353756445061
    Operating Expenses Qtr Cr 3620161545962
    Operating Profit Qtr Cr 0-164-5-9-9-1
    Depreciation Qtr Cr 5964445
    Interest Qtr Cr 11999910
    Tax Qtr Cr 0-20003
    Net Profit Qtr Cr -16-266-18-22-22-18
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 188239
    Operating Expenses Annual Cr 374245
    Operating Profit Annual in Cr -187-8
    Depreciation Cr 10818
    Interest Annual Cr 3640
    Tax Annual Cr -23
    Net Profit Annual Cr -329-68
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 28
    Cash from Investing Activity Annual Cr -16
    Cash from Financing Annual Activity Cr -10
    Net Cash Flow Annual Cr 1
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 39364
    Fixed Assets Annual Cr 456543
    Total Non Current Assets Annual Cr 656759
    Total Current Assets Annual Cr 332507
    Total Assets Annual Cr 9881,266
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 544
    ROE Annual % -833-21
    ROCE Annual % -52-3
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % -100-3

    Vivimed Labs Technicals

    EMA & SMA

    Current Price
    ₹4.9
    -0.1 (-2%)
    • Bullish Moving Average
    • ___
    • 0
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹6.14
    • 50 Day
    • ₹7.75
    • 100 Day
    • ₹8.95
    • 200 Day
    • ₹10.75
    • 20 Day
    • ₹5.94
    • 50 Day
    • ₹8.6
    • 100 Day
    • ₹9.31
    • 200 Day
    • ₹10.15

    Vivimed Labs Resistance and Support

    PIVOT
    ₹5.02
    Resistance
    First Resistance ₹5.19
    Second Resistance ₹5.42
    Third Resistance ₹5.59
    RSI 16.77
    MFI 11.32
    MACD Single Line -1.03
    MACD -0.98
    Support
    First Resistance ₹4.79
    Second Resistance ₹4.62
    Third Resistance ₹4.39

    Vivimed Labs Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day
    Week
    1 Month
    6 Month 25,668 2,566,785 100

    Vivimed Labs Result Highlights

    Vivimed Labs Synopsis

    NSE-Medical-Diversified

    Vivimed Labs is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 176.83 Cr. and Equity Capital is Rs. 16.58 Cr. for the Year ended 31/03/2023. Vivimed Labs Ltd. is a Public Limited Listed company incorporated on 22/09/1988 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L02411KA1988PLC009465 and registration number is 009465.
    Market Cap 41
    Sales 162
    Shares in Float 6.55
    No of funds 5
    Yield
    Book Value 0.31
    U/D Vol ratio
    LTDebt / Equity 46
    Alpha -0.61
    Beta -0.02

    Vivimed Labs

    Owner NameJun-23Mar-23Dec-22Sep-22
    Promoters 20.94%20.94%20.96%20.96%
    Foreign Portfolio Investors 1.64%1.64%1.64%1.64%
    Individual Investors 57%57.08%57.03%57.64%
    Others 20.42%20.34%20.37%19.76%

    Vivimed Labs Management

    Name Designation
    Dr. Jamalapuram Harigopal Chairman & Ind.Director
    Mr. Santosh Varalwar Managing Director
    Dr. Manohar Rao Varalwar Whole Time Director
    Mr. Sandeep Varalwar Whole Time Director
    Mr. Subhash Varalwar Non Executive Director

    Vivimed Labs Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Vivimed Labs Corporate Action

    Date Purpose Remarks
    2023-08-14 Quarterly Results
    2023-05-30 Quarterly Results
    2023-02-13 Quarterly Results
    2023-01-13 A.G.M.
    2022-08-12 Quarterly Results
    • Company Name
    • CMP
    • Chg(%)
    • Company Name
    • CMP
    • Chg(%)

    Vivimed Labs FAQs

    What is Share Price of Vivimed Labs ?

    Vivimed Labs share price is ₹4 As on 30 September, 2023 | 05:17

    What is the Market Cap of Vivimed Labs ?

    The Market Cap of Vivimed Labs is ₹40.6 Cr As on 30 September, 2023 | 05:17

    What is the P/E ratio of Vivimed Labs ?

    The P/E ratio of Vivimed Labs is -0.1 As on 30 September, 2023 | 05:17

    What is the PB ratio of Vivimed Labs ?

    The PB ratio of Vivimed Labs is 1 As on 30 September, 2023 | 05:17

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.